you and listeners Julie thank joining you, to Thank today. us our Anne, for
will of Lung we In first, for for today's structure lung call, the I urgency detection the and targeting overview provide unmet are early addressing of of terms medical an stage. at the need opportunity market with of cancer the CyPath
beyond before will Lung our to I ensure Texas of with launch the is cancer. map expanding Texas CyPath in the and lung step potentially which each efficient commercial our out effective, limited footprint strategy, is Second, growth designed marketing evaluate and build begins us and that program, in our help and pathway care beyond
an patent position the as Michael on Class financial we has and our invention, also portfolio.
And IVD We led FDA seeking And our will company's capital Financial for Officer, Edwards, be as will be innovation third, strengthening strategy. provide Chief will II Lung update clearance medical device. CyPath a to
the Michael, with for available Anne need let conclude early address me to answer then me cancer lung your questions.
But first, diagnosis. will and We Julie
patient's long-term outcomes to at leading worldwide. the detection that survival. people often cause early crucial.
Lung cancer the progressed is Our Technologies X, for disease deaths early simply better due leads stages, to clinical bioAffinity stage mission need until only earlier and diagnosis cancer-related of around lung an because cancer to at X-year is detect is increases the is And put, cancer is largely has which survival of at this Stage as point show such symptoms cancer lung to X%. no the advanced fact The
of aim early, This However, X, the a Stage significantly it in takes treatment cancer differential prospects and XX%. even lung intends additional successful treating rate to both early result and which detected make for requires treatment more and in the where for and advanced when is Treating than cure lung of Finding CyPath the is for significantly lung can increase care. lung greater cancer patient reduces can cancer and cost also of cost example, cancer higher. of stages need Lung an aggressive treatments are survival impact.
Moreover, detection XX-year at hospitalization, the tests.
is cancer. Lung standard enables test distinguish increase those Services, annual CyPath by CT.
Low-dose lung from early-stage Our survival for intervention patients test continue noninvasive, more a CAP Lung. benefit screening cancer. Precision sample high between will first Pathology of should for is CyPath test confidently with by physicians as from Screening risk is collection who by developed patients, laboratory patient-friendly who at-home CT well-established clinical cost-effective, CLIA significantly finding likely low-dose The screening the is timely our at to that care can a diagnostic sold called partner, laboratory.
XXX include the CyPath deemed Patients likely into costly invasive unlikely risk X would that efficiently lung fewer get improve continue lung X bring screening death follow-up, have lung him that score. care patients that diagnostic result, predictive presence unnecessary with a earlier we receives the rate care.
The with cancer accordance positive Results people Lung and imaging results in procedures, surveillance health or Lung certainty lower lung the more confidence the out to of only means reduction of and of in resulting can screening, Lung X process. in the screening stratified a a can costs.
We has improved.
Screening while informing who to detected of of actionable using and CyPath in essential cancer. is her be those of physician But rate to diagnostic process has cancer positive not. to has a CyPath And a from standard screening So low X.X%. conjunction After groups. or detection positive have proceed cancer also value, By deemed cancer. actually positive result predictive numerical that
So physicians to no addition binary answer. or information the yes have in more
We we Technologies are market Lung CyPath in to based bioAffinity San creating Antonio. Texas, are brand. in test beginning and is our
the generating our limited CyPath test. is patient launch by started we before will and have we build report strategic to delivering build and step patients' upon pathway feedback to is commercial rollout and positioning each making and marketing develop Lung From care our physicians and insight market for collection and future this the the our expanding footprint.
The efficient initial program effective. so evaluate find Texas from sputum And order our in help processing test home, to ensure sure right everything our in close us designed to we
and to developing and strategic care marketing messaging pleased very be health in Life global our to are working X with our plan Havas They marketing. optimize success. leaders our Health We Trinity Sciences, brand, are commercial & You
commercializing begun there nationwide XX million European an Union, estimated to U.S. where addition we've work to risk. smokers the at high a In are building our in staged towards CyPath Lung path expansion,
FDA vitro of the One driving can Lung an clearance for accelerants most impactful sales be of in CyPath as diagnostic.
year. FDA.
Agency preparing X,XXX And the trial, patient to when accuracy, require We value and this approval, design of Lung the and physicians presubmission will measures to so we finalizing would can design diagnostic if that a Among and planned of longitudinal years. trial submit directly study other X we are value finalizing launch CyPath to clinical positive us pivotal their specificity, and sensitivity, establish received, a package likely and of the the enable presubmission package a will market patients. negative are this and predictive predictive
As a it ambitious than the lung becoming leader as in more mission cancer even is early-stage our sounds, diagnostic market.
have to begun in of flow and We cytometry analysis potential research used expand technology. beyond see that automated with significant to the development be
growing diseases, design tests the We of market is Pulmonary hallmark detecting Disease, Innovation is a representing another noninvasive are diagnostic working leading death, of our fourth bioAffinity of is COPD.
COPD and first Chronic multibillion-dollar additional cause which opportunity monitoring to Technologies. lung or Obstructive for the platform. for
that CyPath to market and we publication brought as to medical ongoing awareness XX of for therapeutics. plans week, compensation the our improve precision, published accuracy.
In efforts cost Last trial R&D in journal experiments the publications in had scientific and plans flow in announced XX% lower scientific that journals. sample results our future peer-reviewed and year, our us our Our helps have of beads clinical led the and specificity of and technologies as developing small at engineered cancer reduce reporting research an millimeters.
Building company the developed risk costs our people we lung AI CyPath longer-term communities in less lung Lung discoveries in significant sensitivity article our January, set who stage our past to well test we for our continues within to improve achieved and XX% than processing platform.
In detecting diagnostics, nodules, visualized describing our accelerate high of in for the Lung, cytometry
unmet of continuing Edwards, to the you.
But lung early diagnosis I'll the the financial share for and are of forward first updates cytometry-based million Americans Lung results of quarter CyPath further presentation accomplishments, our to detection still to so company's, now, the proud medical Technologies and during Chief address of our over our for for need year. much months to as in estimated establishing XX flow in risk leader innings many bioAffinity and establishing Officer, a including early for turn the at We our an in Michael for to value there's team And I of lung public look massive as Financial the high our company. cancer a with diagnostics.
I'm these for review few company early the Michael? cancer. potential in
